Bulk Pharmaceutical API Sources for SANDIMMUNE

Bulk Pharmaceutical API Sources for SANDIMMUNE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		C3662_SIGMA
Sigma-Aldrich		C1832_SIGMA
Sigma-Aldrich		30024_SIGMA
Molport		MolPort-006-705-994
TCI (Tokyo Chemical Industry)		C2408
Amadis Chemical		A832514

SANDIMMUNE (Cyclosporine) Bulk Active Pharmaceutical Ingredient Sources

Last updated: February 19, 2026

This analysis identifies and characterizes key suppliers of bulk active pharmaceutical ingredient (API) for SANDIMMUNE (cyclosporine), a calcineurin inhibitor used as an immunosuppressant. The focus is on API manufacturing capabilities, regulatory compliance, and supply chain considerations relevant to pharmaceutical companies.

What is Cyclosporine and its Therapeutic Applications?

Cyclosporine is a cyclic undecapeptide with potent immunosuppressive properties. Its primary mechanism of action involves inhibiting the calcineurin pathway, which is crucial for T-cell activation and proliferation. This inhibition prevents the release of pro-inflammatory cytokines, thereby suppressing the immune response.

Primary therapeutic uses for cyclosporine include:

• Organ Transplantation: Prevention of organ rejection following kidney, liver, heart, and lung transplants.
• Autoimmune Diseases: Treatment of conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, and uveitis.
• Graft-versus-Host Disease (GvHD): Prevention and treatment of GvHD following stem cell transplantation.

Cyclosporine is available in various formulations, including oral capsules, oral solutions, and intravenous injections, each requiring high-quality bulk API for consistent drug product performance.

Major Manufacturers of Cyclosporine API

The global market for cyclosporine API is characterized by a mix of large pharmaceutical companies with integrated manufacturing and specialized API producers. Key players are assessed based on their production capacity, regulatory approvals, and geographical presence.

Table 1: Key Cyclosporine API Manufacturers and Locations

Manufacturer Name	Primary Location(s) of API Manufacturing	Regulatory Approvals (Examples)	Key Products (API)
Novartis	Switzerland, United States	FDA, EMA	Cyclosporine
AbbVie Inc.	United States	FDA	Cyclosporine
Bristol-Myers Squibb	United States	FDA	Cyclosporine
Sun Pharmaceutical Industries Ltd.	India	US FDA, EDQM, WHO GMP	Cyclosporine
Cipla Ltd.	India	US FDA, EMA, TGA	Cyclosporine
Dr. Reddy's Laboratories	India	US FDA, EMA, PMDA	Cyclosporine
Teva Pharmaceutical Industries	Israel	US FDA, EMA	Cyclosporine
Sandoz (part of Novartis)	Switzerland, Slovenia, Austria	FDA, EMA	Cyclosporine

Note: This list is not exhaustive but represents significant global suppliers. Many smaller regional API manufacturers also exist.

Regulatory Landscape and Quality Standards

The production of bulk cyclosporine API is subject to stringent regulatory oversight to ensure product safety, efficacy, and quality. Key regulatory bodies and standards include:

• U.S. Food and Drug Administration (FDA): Requires adherence to current Good Manufacturing Practices (cGMP) and submission of Drug Master Files (DMFs).
• European Medicines Agency (EMA): Mandates compliance with EU GMP and facilitates Certificate of Suitability (CEP) issuance by the European Directorate for the Quality of Medicines & HealthCare (EDQM).
• Pharmaceutical Inspection Co-operation Scheme (PIC/S): A global initiative to harmonize inspection procedures for GMP.
• World Health Organization (WHO) GMP: Standards applicable for medicines distributed globally.

Drug Master Files (DMFs) and Certificates of Suitability (CEPs)

API manufacturers commonly file DMFs with regulatory agencies like the FDA. These confidential documents contain detailed information about the manufacturing process, facilities, and quality control of the API. Pharmaceutical companies cite these DMFs in their drug product marketing applications.

CEPs, issued by the EDQM, are a significant indicator of API quality for the European market. A CEP certifies that the API complies with the requirements of the European Pharmacopoeia monograph for cyclosporine.

Table 2: Regulatory Filings and Certifications for Select Cyclosporine API Suppliers

Manufacturer	US DMF Status	EU CEP Status	Other Key Certifications
Sun Pharmaceutical Industries Ltd.	Active	Issued	WHO GMP, KFDA
Cipla Ltd.	Active	Issued	TGA, Health Canada
Dr. Reddy's Laboratories	Active	Issued	PMDA, ANVISA
Novartis (API Division)	Active	Issued	Health Canada, TGA

Note: Regulatory statuses are dynamic and subject to change. Companies should verify current filings and certifications directly.

Manufacturing Processes and Quality Control

The synthesis of cyclosporine is a complex multi-step process. Cyclosporine is a naturally occurring cyclic peptide produced by fermentation of the fungus Tolypocladium inflatum. The subsequent isolation and purification steps are critical for achieving the required purity and impurity profile.

Key aspects of API manufacturing and quality control include:

• Fermentation Control: Optimizing microbial strain, media composition, temperature, and aeration to maximize cyclosporine yield and minimize by-product formation.
• Extraction and Isolation: Efficiently recovering cyclosporine from the fermentation broth using solvent extraction techniques.
• Purification: Employing chromatography (e.g., High-Performance Liquid Chromatography - HPLC) and crystallization to remove impurities and achieve high purity levels.
• Impurity Profiling: Identifying and quantifying process-related impurities, degradation products, and residual solvents, often guided by pharmacopoeial limits (e.g., USP, EP).
• Chiral Purity: Ensuring the correct stereochemistry of the peptide chain, as stereoisomers can affect efficacy and safety.
• Batch Consistency: Implementing robust in-process controls and final API testing to ensure batch-to-batch uniformity.

Table 3: Critical Quality Attributes for Cyclosporine API

Attribute	Typical Specification Range	Analytical Method (Example)
Assay (HPLC)	≥ 98.0%	HPLC
Related Substances	≤ 0.1% (Individual Impurity)	HPLC
Water Content (Karl Fischer)	≤ 1.0%	KF Titration
Residual Solvents	USP <467> Limits	GC
Specific Rotation	Defined range	Polarimetry
Heavy Metals	≤ 10 ppm	USP <231> or equivalent
Microbial Limits	Compliant with Pharmacopoeia	Microbial Enumeration Tests

Note: Specific acceptance criteria are defined by individual pharmacopoeias and the API manufacturer's DMF.

Supply Chain Considerations and Risk Mitigation

Pharmaceutical companies sourcing bulk cyclosporine API must consider supply chain resilience and potential risks.

Key considerations:

• Geopolitical Stability: Reliance on a single region for API manufacturing can pose risks due to political instability, trade disputes, or natural disasters. Diversifying supplier geography is a mitigation strategy.
• Regulatory Changes: Evolving regulatory requirements or stricter enforcement can impact API availability or require manufacturers to update processes. Proactive engagement with suppliers on their regulatory compliance is essential.
• Capacity and Lead Times: Understanding a supplier's production capacity and typical lead times is crucial for production planning and avoiding shortages.
• Quality Audits: Regular on-site quality audits of API manufacturers are critical to verify cGMP compliance and ensure ongoing quality.
• Intellectual Property: While the patent for Sandimmune (cyclosporine) has long expired, understanding the patent landscape for novel formulations or delivery systems of cyclosporine is important for new product development.

Table 4: Geographic Distribution of Key Cyclosporine API Manufacturing Sites

Region	Number of Major Manufacturers (Approx.)
India	3-5
United States	2-4
Europe	1-2
Israel	1

The concentration of manufacturing in certain regions, particularly India, highlights the importance of robust supplier qualification and risk management processes.

Future Trends in Cyclosporine API Supply

The market for cyclosporine API is largely mature, with established players and significant generic competition. Future trends may include:

• Process Optimization: Continuous efforts by API manufacturers to improve fermentation yields, reduce extraction and purification costs, and enhance sustainability of manufacturing processes.
• Emerging Market Expansion: Increased API production capacity in emerging markets to serve growing demand for generic immunosuppressants.
• Enhanced Analytical Techniques: Adoption of advanced analytical methods for impurity detection and characterization to meet increasingly stringent regulatory expectations.
• Supply Chain Transparency: Greater demand for end-to-end supply chain visibility from raw materials to finished API.

Key Takeaways

• Cyclosporine API is primarily manufactured by a limited number of global pharmaceutical and specialized API producers, with significant presence in India and the United States.
• Regulatory compliance, evidenced by FDA DMFs and EDQM CEPs, is paramount for API suppliers.
• Stringent quality control, including impurity profiling and adherence to pharmacopoeial standards, is critical for cyclosporine API.
• Supply chain diversification and rigorous supplier audits are essential risk mitigation strategies for pharmaceutical companies.

FAQs

What is the typical purity requirement for bulk cyclosporine API?

Bulk cyclosporine API typically requires a purity of not less than 98.0% as determined by High-Performance Liquid Chromatography (HPLC). Specific limits for individual and total impurities are also defined by pharmacopoeias and manufacturer specifications.

Are there any significant patent barriers for generic cyclosporine API production?

The primary patents for Sandimmune (cyclosporine) have long expired. Generic API production is generally unencumbered by composition-of-matter patents for the active ingredient itself. However, new formulations or manufacturing process patents could exist for specific drug products.

How frequently should a pharmaceutical company audit its cyclosporine API supplier?

Auditing frequency depends on the supplier's risk profile, regulatory history, and the criticality of the API to the finished drug product. A common practice is to conduct initial comprehensive audits and subsequent periodic audits, which can range from annually to every three years, or on an as-needed basis following quality events.

What are the main impurities that need to be controlled in cyclosporine API?

Key impurities to control include process-related impurities arising from the fermentation and purification steps, such as related peptides and degradation products. Residual solvents used during manufacturing and potential heavy metals are also critical. Pharmacopoeias provide specific guidance on acceptable impurity limits.

Can cyclosporine API be sourced from manufacturers without US FDA or EU EMA approval?

While it may be possible to source API from manufacturers without direct US FDA or EU EMA approval, this poses significant regulatory risks. Drug product manufacturers must be able to support their marketing applications with compliant API. APIs sourced from unapproved facilities would likely require extensive validation and justification, often making them unsuitable for regulated markets.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: Drug Master Files. Retrieved from [FDA website] (Specific URL not provided as it is a dynamic page and may change).

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP). Retrieved from [EDQM website] (Specific URL not provided as it is a dynamic page and may change).

[3] United States Pharmacopeia. (n.d.). Cyclosporine Monograph. In United States Pharmacopeia and National Formulary.

[4] European Pharmacopoeia. (n.d.). Cyclosporine Monograph. In European Pharmacopoeia.

[5] World Health Organization. (2010). WHO Good manufacturing practices for pharmaceutical products: Main principles. WHO Technical Report Series, 961.